semaglutide fda approval history A big win for Wegovy: Weight loss drug first in to gain for reducing heart risks WEGOVY: Leading the Charge in

Thats perhaps unsurprising given the estimated number of consumers taking GLP-1 drugs like Wegovy, Ozempic, or Mounjaro

The healthcare industry is at its best when innovation, safety, and patient access work together

"Not medically necessary" or "step therapy required" = PA denial (you can appeal) "Excluded benefit" or "not covered" = your plan's formulary differs from standard (request exception) WHAT'S COMING Aetna Coverage Outlook for 2026 Wegovy Coverage Expected to Continue in 2026 CVS Caremark's deal with Novo Nordisk positions Wegovy as the primary GLP-1 option for Aetna plans

Researchers are studying its effects on: Body weight reduction Body Mass Index (BMI) Waist circumference Blood glucose regulation Insulin sensitivity Liver fat content Cardiovascular risk factors Overall metabolic health Long-term safety and tolerability Although early clinical research has produced encouraging results, additional studies are needed before Retatrutide becomes part of routine medical practice

Such individuals may choose to work with their care providers to devise a treatment plan that makes use of unapproved or off-label therapies after careful consideration of and counseling regarding the potential risks and benefits